Biocytogen Pharmaceuticals Makes HKSE Debut with USD 70 Million IPO
Sino-US contract research organization (CRO) Biocytogen Pharmaceuticals (Beijing) Co., Ltd has completed an initial public...
Immunotherapy
Sunshine Guojian’s SSGJ-608 Hits Primary Endpoint in Psoriasis Study
China-based Sunshine Guojian Pharmaceutical (Shanghai) Co., Ltd, a subsidiary of 3SBio Inc. (HKG: 1530), announced...
Harbin Gloria Partners with Genolmmune on PD-1 and Neoantigen Therapy for NSCLC
China-based Harbin Gloria Pharmaceuticals Co., Ltd (SHE: 002437) has partnered with Genolmmune Therapeutics Biotechnology Co.,...
CSPC Pharmaceutical’s JMT103 Anti-RANKL Antibody Prioritized for CDE Review
China-based CSPC Pharmaceutical Group Ltd (HKG: 1093) announced that its market filing for JMT103, an...
Rakuten Medical Taiwan Administers First Dose of ASP-1929 in Phase II Trial
Rakuten Medical Taiwan Inc. announced the administration of its photo-immunotherapy ASP-1929 to the first patient...
InnoCare and Keymed Biosciences’ CCR8-Targeted mAb CM369 Accepted by NMPA
China-based InnoCare (HKG: 9969) and Keymed Biosciences Inc. (HKG: 2162) announced that an Investigational New...
Mabwell’s 6MW3511 Accepted by NMPA for Advanced Solid Tumor Treatment
China-based Mabwell (Shanghai) Bioscience Co., Ltd (SHA: 688062) announced that a clinical trial filing for...
Yabao Pharmaceutical’s YBSW015 Gets Australian Ethical Approval for COVID-19 Trial
China-based Yabao Pharmaceutical Group Co., Ltd (SHA: 600351) has announced that it has received clinical...